CD274 and non-small cell lung carcinoma: In the OAK study comparing atezolizumab with docetaxel in previously treated NSCLC patients, as measured by Ventana SP142, the subgroup with PD-L1 expression on ≥50% of TCs or ICs benefited most from atezolizumab; OS and HR were 20.5 months and 0.41, respectively, and 8.9 months and 0.75 for patients without PD-L1 expression on TCs or ICs, respectively [20].